Business UpdateJul 14, 2026, 05:27 PM
Nordicus Biotech Advances 2 Drugs to Phase IIa; Applies for Nasdaq Uplist
AI Summary
Nordicus Partners Corp, a U.S. publicly listed biotech company, announced significant progress in its drug development pipeline, with Orocidin A/S and Bio-Convert A/S both anticipating Phase IIa clinical trials in the first half of 2027 for periodontitis and oral leukoplakia, respectively. The company also formed a new subsidiary, NoviThera ApS, in October 2025 to develop a psoriasis treatment, which has completed biological proof of concept. Additionally, Nordicus applied to uplist its common stock to the Nasdaq Capital Market in September 2025. Financially, the company saw increased cash usage in operating activities and higher R&D and professional fees for the fiscal year ended March 31, 2026.
Key Highlights
- Applied to uplist common stock to the Nasdaq Capital Market in September 2025.
- Orocidin A/S's QR-01 for periodontitis is anticipated to begin Phase IIa clinical trials in H1 2027.
- Bio-Convert A/S's QR-02 for oral leukoplakia is anticipated to begin Phase IIa clinical trials in H1 2027.
- Formed NoviThera ApS in October 2025 for psoriasis treatment, completing biological proof of concept.
- Repurchased 57,642 shares of common stock at $1.36 per share in October 2025.
- Cash used in operating activities increased to $4.32 million in FY26 from $1.28 million in FY25.
- Research and development expense increased 21% to $1.61 million in FY26.
- Professional fees increased 167% to $940,727 in FY26.
Price Impact
More from NORD